CareDx Divests Lab Products Business for $170M, Reports Strong Preliminary Q1 Growth in Core Segments

summarizeSummary

CareDx is selling its Lab Products business for $170 million to EuroBio Scientific, a strategic divestiture aimed at focusing on core precision medicine and digital solutions, while also reporting strong preliminary Q1 2026 revenue growth.

check_boxKey Events

• Divestiture of Lab Products Business

  CareDx entered a definitive agreement to divest its Lab Products business to EuroBio Scientific for $170 million in cash. This includes the sale of CareDx's Swedish entity and related assets.

• Strategic Focus and Financial Flexibility

  The divestiture is expected to sharpen CareDx's focus on its core Precision Medicine Testing Services and Patient and Digital Solutions, improve financial flexibility, and support AEBITDA margin expansion. Proceeds will be prioritized for growth investments and potential capital return to shareholders.

• Strong Preliminary Q1 2026 Financial Results

  CareDx reported preliminary unaudited Q1 2026 revenue of approximately $118 million, representing 39% year-over-year growth. Testing Service revenue grew 48% year-over-year to $91 million, and Patient and Digital Solutions revenue grew 33% year-over-year to $16 million.

• Retained Distribution Rights

  CareDx retains the sole and exclusive perpetual right to distribute post-transplant monitoring IVD tests in North America, including AlloSeq cfDNA.

auto_awesomeAnalysis

CareDx is strategically divesting its Lab Products business to EuroBio Scientific for $170 million in cash, a significant transaction representing approximately 18.9% of its current market capitalization. This move is intended to sharpen the company's focus on its core Precision Medicine Testing Services and Patient and Digital Solutions, improve financial flexibility, and simplify its operating model. The company also reported strong preliminary first-quarter 2026 results, with overall revenue up 39% year-over-year, driven by substantial growth in its targeted core segments. The cash proceeds are expected to support long-term growth strategies and potentially include capital return to shareholders. The transaction is subject to Swedish regulatory review and is anticipated to close by the third quarter of 2026.